JP2014504866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504866A5 JP2014504866A5 JP2013547846A JP2013547846A JP2014504866A5 JP 2014504866 A5 JP2014504866 A5 JP 2014504866A5 JP 2013547846 A JP2013547846 A JP 2013547846A JP 2013547846 A JP2013547846 A JP 2013547846A JP 2014504866 A5 JP2014504866 A5 JP 2014504866A5
- Authority
- JP
- Japan
- Prior art keywords
- single variable
- variable domain
- immunoglobulin single
- polypeptide
- tgfbetarii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430235P | 2011-01-06 | 2011-01-06 | |
| US61/430,235 | 2011-01-06 | ||
| PCT/EP2012/050061 WO2012093125A1 (en) | 2011-01-06 | 2012-01-04 | Ligands that bind tgf-beta receptor ii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016205978A Division JP6453289B2 (ja) | 2011-01-06 | 2016-10-20 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504866A JP2014504866A (ja) | 2014-02-27 |
| JP2014504866A5 true JP2014504866A5 (enExample) | 2015-01-08 |
| JP6062375B2 JP6062375B2 (ja) | 2017-01-18 |
Family
ID=45444622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013547846A Expired - Fee Related JP6062375B2 (ja) | 2011-01-06 | 2012-01-04 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
| JP2016205978A Expired - Fee Related JP6453289B2 (ja) | 2011-01-06 | 2016-10-20 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016205978A Expired - Fee Related JP6453289B2 (ja) | 2011-01-06 | 2016-10-20 | Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9150651B2 (enExample) |
| EP (1) | EP2661449B1 (enExample) |
| JP (2) | JP6062375B2 (enExample) |
| KR (1) | KR101886898B1 (enExample) |
| CN (1) | CN103443126B (enExample) |
| AU (1) | AU2016203609A1 (enExample) |
| BR (1) | BR112013016917A2 (enExample) |
| CA (1) | CA2823104A1 (enExample) |
| CL (1) | CL2013001975A1 (enExample) |
| CO (1) | CO6811807A2 (enExample) |
| CR (1) | CR20130376A (enExample) |
| DO (1) | DOP2013000162A (enExample) |
| EA (1) | EA201391012A1 (enExample) |
| ES (1) | ES2627299T3 (enExample) |
| IL (1) | IL227254A0 (enExample) |
| MA (1) | MA34820B1 (enExample) |
| MX (1) | MX2013007936A (enExample) |
| PE (1) | PE20140982A1 (enExample) |
| PH (1) | PH12013501397A1 (enExample) |
| SG (1) | SG191762A1 (enExample) |
| WO (1) | WO2012093125A1 (enExample) |
| ZA (1) | ZA201304726B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PE20140982A1 (es) * | 2011-01-06 | 2014-08-22 | Glaxo Group Ltd | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta |
| HUE031828T2 (en) | 2011-06-23 | 2017-08-28 | Ablynx Nv | Procedures for Predicting, Detecting, and Reducing Aspiration Protein Interference in Assays Containing Immunoglobulin Variable Single Domain |
| BR112015023262B8 (pt) * | 2013-03-15 | 2024-02-06 | Ac Immune Sa | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo |
| SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| EP2992010B1 (en) | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| AU2014308751B2 (en) | 2013-08-22 | 2020-03-05 | Acceleron Pharma, Inc. | TGF-beta receptor type II variants and uses thereof |
| EP4417255A3 (en) * | 2013-11-21 | 2024-10-23 | The Brigham and Women's Hospital Inc. | Compositions and methods for treating pulmonary hypertension |
| BR112016016411A2 (pt) * | 2014-01-15 | 2017-10-03 | Hoffmann La Roche | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS |
| BR112016014969A2 (pt) | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo |
| JP6955443B2 (ja) | 2014-08-01 | 2021-10-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 肺動脈性肺高血圧症の処置に関する方法および組成物 |
| CR20210429A (es) | 2015-06-24 | 2021-09-24 | Hoffmann La Roche | ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562) |
| CN116327952A (zh) | 2015-08-04 | 2023-06-27 | 阿塞勒隆制药公司 | 用于治疗骨髓增生性病症的方法 |
| WO2017041114A2 (en) * | 2015-09-03 | 2017-03-09 | The Children's Mercy Hospital | Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
| ES2905912T3 (es) * | 2015-11-13 | 2022-04-12 | Ablynx Nv | Dominios variables de inmunoglobulina de unión a albúmina sérica mejorados |
| JP2019510786A (ja) * | 2016-04-05 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 免疫療法におけるＴＧＦβの阻害 |
| BR112019023071A2 (pt) | 2017-05-04 | 2020-06-09 | Acceleron Pharma Inc | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas |
| GB201807693D0 (en) * | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| WO2020009248A1 (ja) * | 2018-07-04 | 2020-01-09 | 京都府公立大学法人 | 眼組織の線維化抑制用組成物 |
| US20220362333A1 (en) * | 2019-07-26 | 2022-11-17 | Board Of Trustees Of Michigan State University | Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle |
| JP7633259B2 (ja) * | 2019-12-24 | 2025-02-19 | メルス ナムローゼ フェンノートシャップ | ＴＧＦ－βＲＩＩ結合タンパク質 |
| KR102314157B1 (ko) * | 2020-01-10 | 2021-10-19 | 주식회사 뉴클릭스바이오 | TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법 |
| WO2022099090A1 (en) * | 2020-11-06 | 2022-05-12 | Xencor, Inc. | Heterodimeric antibodies that bind tgfbrii |
| JP2024506200A (ja) | 2021-02-15 | 2024-02-09 | 武田薬品工業株式会社 | 細胞治療用組成物及びｔｇｆ－ｂシグナル伝達を調節する方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| JP2001206899A (ja) * | 1999-11-18 | 2001-07-31 | Japan Tobacco Inc | ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途 |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| EP1600459A3 (en) | 2002-06-28 | 2005-12-07 | Domantis Limited | Ligand |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| JP2006523090A (ja) | 2002-12-27 | 2006-10-12 | ドマンティス リミテッド | リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体 |
| US20090005257A1 (en) | 2003-05-14 | 2009-01-01 | Jespers Laurent S | Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire |
| SI1639011T1 (sl) | 2003-06-30 | 2009-04-30 | Domantis Ltd | Pegilirana protitelesa z enojno domeno (dAb) |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| JP5010923B2 (ja) | 2004-02-09 | 2012-08-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合蛋白質 |
| PL1737962T3 (pl) | 2004-03-24 | 2011-02-28 | Domantis Ltd | Uniwersalny lider GAS1 |
| GB0418651D0 (en) | 2004-08-20 | 2004-09-22 | Medical Res Council | Method |
| US20070012251A1 (en) | 2005-07-07 | 2007-01-18 | Martin Zucker | Seal arrangement with corrosion barrier and method |
| TW200804593A (en) | 2006-01-24 | 2008-01-16 | Domantis Ltd | Fusion proteins that contain natural junctions |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| KR20120063475A (ko) * | 2009-07-29 | 2012-06-15 | 글락소 그룹 리미티드 | 항-ｔｇｆ-베타 수용체 타입 ⅱ 단일 도메인 항체 |
| EP2496600A1 (en) * | 2009-11-04 | 2012-09-12 | Fabrus LLC | Methods for affinity maturation-based antibody optimization |
| PE20140982A1 (es) * | 2011-01-06 | 2014-08-22 | Glaxo Group Ltd | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta |
-
2012
- 2012-01-04 PE PE2013001516A patent/PE20140982A1/es not_active Application Discontinuation
- 2012-01-04 BR BR112013016917A patent/BR112013016917A2/pt not_active Application Discontinuation
- 2012-01-04 CN CN201280012010.6A patent/CN103443126B/zh not_active Expired - Fee Related
- 2012-01-04 WO PCT/EP2012/050061 patent/WO2012093125A1/en not_active Ceased
- 2012-01-04 ES ES12700019.8T patent/ES2627299T3/es active Active
- 2012-01-04 JP JP2013547846A patent/JP6062375B2/ja not_active Expired - Fee Related
- 2012-01-04 US US13/978,228 patent/US9150651B2/en not_active Expired - Fee Related
- 2012-01-04 MX MX2013007936A patent/MX2013007936A/es not_active Application Discontinuation
- 2012-01-04 PH PH1/2013/501397A patent/PH12013501397A1/en unknown
- 2012-01-04 EA EA201391012A patent/EA201391012A1/ru unknown
- 2012-01-04 MA MA36101A patent/MA34820B1/fr unknown
- 2012-01-04 CA CA2823104A patent/CA2823104A1/en not_active Abandoned
- 2012-01-04 KR KR1020137020615A patent/KR101886898B1/ko not_active Expired - Fee Related
- 2012-01-04 EP EP12700019.8A patent/EP2661449B1/en active Active
- 2012-01-04 SG SG2013049663A patent/SG191762A1/en unknown
-
2013
- 2013-06-25 ZA ZA2013/04726A patent/ZA201304726B/en unknown
- 2013-06-27 IL IL227254A patent/IL227254A0/en unknown
- 2013-07-03 DO DO2013000162A patent/DOP2013000162A/es unknown
- 2013-07-05 CL CL2013001975A patent/CL2013001975A1/es unknown
- 2013-07-16 CO CO13168686A patent/CO6811807A2/es unknown
- 2013-08-05 CR CR20130376A patent/CR20130376A/es unknown
-
2015
- 2015-09-02 US US14/843,250 patent/US9850307B2/en not_active Expired - Fee Related
-
2016
- 2016-05-31 AU AU2016203609A patent/AU2016203609A1/en not_active Abandoned
- 2016-10-20 JP JP2016205978A patent/JP6453289B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-21 US US15/818,861 patent/US20180086835A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211053T1 (hr) | Modificirani fgf-21 polipeptidi i njihove primjene | |
| PH12013501397A1 (en) | Ligands that bind tgf-beta receptor ii | |
| JP2014158480A5 (enExample) | ||
| JP2017537612A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2011514150A5 (enExample) | ||
| JP2017081939A5 (enExample) | ||
| EP4317185A3 (en) | Fully-human post-translationally modified antibody therapeutics | |
| JP2016536361A5 (enExample) | ||
| JP2017101068A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2012511545A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2013520996A5 (enExample) | ||
| NZ607394A (en) | Vegf-binding molecules | |
| JP2016502515A5 (enExample) | ||
| HRP20200936T1 (hr) | Antitijela za beta amiloid | |
| JP2011519571A5 (enExample) | ||
| RU2018147413A (ru) | PD-L1 специфические антитела | |
| JP2011506483A5 (enExample) | ||
| JP2015533795A5 (enExample) | ||
| AR078515A1 (es) | Moleculas de union biespecificas de union a vegf (factor de crecimiento endotelial vascular) y a dll4 (ligando 4 de tipo delta) para la terapia anti-angiogenesis | |
| PE20080112A1 (es) | Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas | |
| HRP20140604T1 (hr) | Sredstva koja djeluju na cd138 i njihova upotreba |